Home > Insider Trading > Filing (0000899243-23-011461)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1658551	Amylyx Pharmaceuticals Inc.	AMLX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1358266	D Patrick Yeramian	C/O Amylyx Pharmaceuticals, Inc. 43 Thorndike Street Cambridge MA 02141	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-04-17	44,861	$0.37	253,278	No	4	M	Direct
Common Stock	Acquisiton	2023-04-17	4,718	$6.88	257,996	No	4	M	Direct
Common Stock	Disposition	2023-04-17	49,279	$30.53	208,717	No	4	S	Direct
Common Stock	Disposition	2023-04-17	300	$30.94	208,417	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2023-04-17	44,861	$0.00	44,861	$0.37
Common Stock	Stock Option (right to buy)	Disposition	2023-04-17	4,718	$0.00	4,718	$6.88

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,605		2029-03-18	No	4	M	Direct
43,534		2031-02-21	No	4	M	Direct

Footnotes

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.93 to $30.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
As of the date of this filing, 44,861 shares subject to the option are vested and exercisable. 17,605 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.
As of the date of this filing, 18,464 shares subject to the option are vested and exercisable. 29,788 shares subject to such option vest and become exercisable in substantially equal monthly installments until December 19, 2023.